Cascio et al., 2021 - Google Patents
Cancer-associated MSC drive tumor immune exclusion and resistance to immunotherapy, which can be overcome by Hedgehog inhibitionCascio et al., 2021
View PDF- Document ID
- 16021784966769492957
- Author
- Cascio S
- Chandler C
- Zhang L
- Sinno S
- Gao B
- Onkar S
- Bruno T
- Vignali D
- Mahdi H
- Osmanbeyoglu H
- Vlad A
- Coffman L
- Buckanovich R
- Publication year
- Publication venue
- Science advances
External Links
Snippet
We investigated the impact of cancer-associated mesenchymal stem cells (CA-MSCs) on ovarian tumor immunity. In patient samples, CA-MSC presence inversely correlates with the presence of intratumoral CD8+ T cells. Using an immune “hot” mouse ovarian cancer model …
- 206010028980 Neoplasm 0 title abstract description 200
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
- C12N5/0602—Vertebrate cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Cascio et al. | Cancer-associated MSC drive tumor immune exclusion and resistance to immunotherapy, which can be overcome by Hedgehog inhibition | |
Alam et al. | Fungal mycobiome drives IL-33 secretion and type 2 immunity in pancreatic cancer | |
Engblom et al. | Osteoblasts remotely supply lung tumors with cancer-promoting SiglecFhigh neutrophils | |
De Henau et al. | Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells | |
Loeuillard et al. | Targeting tumor-associated macrophages and granulocytic myeloid-derived suppressor cells augments PD-1 blockade in cholangiocarcinoma | |
Moral et al. | ILC2s amplify PD-1 blockade by activating tissue-specific cancer immunity | |
Aguilera et al. | Reprogramming the immunological microenvironment through radiation and targeting Axl | |
Meyer et al. | Breast and pancreatic cancer interrupt IRF8-dependent dendritic cell development to overcome immune surveillance | |
Fan et al. | The characteristics of tumor microenvironment in triple negative breast cancer | |
Cao et al. | BMP4 inhibits breast cancer metastasis by blocking myeloid-derived suppressor cell activity | |
Peran et al. | Cadherin 11 promotes immunosuppression and extracellular matrix deposition to support growth of pancreatic tumors and resistance to gemcitabine in mice | |
Senechal et al. | Expansion of regulatory T cells in patients with Langerhans cell histiocytosis | |
Ngo et al. | Antibody therapy targeting CD47 and CD271 effectively suppresses melanoma metastasis in patient-derived xenografts | |
Wolk et al. | IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-γ are not | |
Li et al. | Gr‐1+ CD11b+ cells are responsible for tumor promoting effect of TGF‐β in breast cancer progression | |
Zhang et al. | Characterization of arginase expression in glioma-associated microglia and macrophages | |
LaMarche et al. | An IL-4 signalling axis in bone marrow drives pro-tumorigenic myelopoiesis | |
Araujo et al. | Stromal oncostatin M cytokine promotes breast cancer progression by reprogramming the tumor microenvironment | |
Simoncello et al. | CXCL5-mediated accumulation of mature neutrophils in lung cancer tissues impairs the differentiation program of anticancer CD8 T cells and limits the efficacy of checkpoint inhibitors | |
Carbotti et al. | The IL-18 antagonist IL-18–binding protein is produced in the human ovarian cancer microenvironment | |
Kinoshita et al. | Interleukin-38 promotes tumor growth through regulation of CD8+ tumor-infiltrating lymphocytes in lung cancer tumor microenvironment | |
Oliveira et al. | Preexisting tumor-resident T cells with cytotoxic potential associate with response to neoadjuvant anti–PD-1 in head and neck cancer | |
Stavre et al. | A role for neutrophils in early enthesitis in spondyloarthritis | |
Barik et al. | Normalization of tumor microenvironment by neem leaf glycoprotein potentiates effector T cell functions and therapeutically intervenes in the growth of mouse sarcoma | |
Sarhan et al. | Targeting myeloid suppressive cells revives cytotoxic anti-tumor responses in pancreatic cancer |